Modification of fibrin structure as a possible cause of thrombolytic resistance

Journal of Thrombosis and Thrombolysis

Volumn 29, Issue 3, 2010, Pages 296-298

  Lipinski, Boguslaw ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Chelating agents; Fibrin(ogen); Free radical scavengers; Free radicals; Proteolysis

Indexed keywords

ACETYLSALICYLIC ACID; ASCORBIC ACID; COPPER ION; DISUFENTON SODIUM; FIBRIN; FIBRINOLYTIC AGENT; HEPARINOID; HYDROXYL RADICAL; IRON; IRON CHELATING AGENT; PLASMIN; POLYPHENOL DERIVATIVE; RESVERATROL; SALICYLIC ACID DERIVATIVE; TISSUE PLASMINOGEN ACTIVATOR; CHELATING AGENT; FREE RADICAL; PEPTIDE HYDROLASE; SCAVENGER;

ARTICLE; BLOOD CLOT LYSIS; BRAIN ISCHEMIA; CAUSAL ATTRIBUTION; DISULFIDE BOND; DRUG HYDROXYLATION; DRUG POTENTIATION; DRUG SENSITIVITY; FENTON REACTION; FIBRIN CLOT; FIBRIN METABOLISM; FIBRINOLYTIC THERAPY; HEART INFARCTION; HUMAN; IRON CHELATION; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN MODIFICATION; PROTEIN STRUCTURE; REACTION TIME; THROMBUS; ANIMAL; CHEMISTRY; DRUG EFFECTS; DRUG RESISTANCE; METABOLISM; PHYSIOLOGY; PROCEDURES; THROMBOSIS;

ANIMALS; CHELATING AGENTS; DRUG RESISTANCE; FIBRIN; FREE RADICAL SCAVENGERS; FREE RADICALS; HUMANS; PEPTIDE HYDROLASES; THROMBOLYTIC THERAPY; THROMBOSIS;

EID: 77957965529     PISSN: 09295305     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11239-009-0367-6     Document Type: Article

References (32)

1. Husain SS, Lipinski B, Gurewich V (1981) Rapid purification of a high-affinity plasminogen activator from human blood. Proc Natl Acad Sci USA 78:4265-4569
2. Hill MD, Buchan AM (2005) Thrombolysis for acute ischemic stroke: results of the Canadian alteplase for stroke effectiveness study. CMAJ 172:1307-1312
3. Prentice CR et al (1993) The fibrinolytic response to ancrod therapy: characterization of fibrinogen and fibrin degradation products. Br J Haematol 83:276-281
4. Wiman B (1999) Predictive value of fibrinolytic factors in coronary heart disease. Scan J Clin Lab Invest Suppl 230:23-31
5. Lipinski B, Nowak A, Gurewich V (1974) Fibrinolysis versus fibrinogenolysis in man: resistance of fibrinogen to breakdown by fibrinolytic activity induced by venous occlusion. Experientia 30:84-85
6. Steinmann C et al (1994) A new substitution, gamma 358 Ser->Cys, in fibrinogen Milano VII causes defective fibrin polymerization. Blood 84:1874-1880
7. Koopman J et al (1993) Molecular basis for fibrinogen Dusart (Alpha 554Arg->Cys) associated with abnormal fibrinogen polymerization and thrombophilia. J Clin Invest 91:1637-1643
8. Lipinski B (1995) In vitro preparation and partial characterization of a novel complex of human fibrinogen with albumin. J Prot Chem 14:259-262
9. Lipinski B, Sajdel-Sulkowska E (2006) New insight into Alzheimer disease: demonstration of fibrin (ogen)-serum albumin insoluble deposits in brain tissue. Alzheimer Dis Assoc Disord 20:323-326
10. Lipinski B (2001) Pathophysiology of oxidative stress in diabetes mellitus. J Diabetes Complic 15:203-210
11. Lipinski B, Federman AM, Krolewski AS (1995) Plasma macromolecular protein complex: Interaction with fibrin and fibrinolysis. Thromb Res 78:461-465
12. Karpel R, Marx G, Chevion M (1991) Free radical induced fibrinogen coagulation: modulation of neofibe formation by concentration, pH, and temperature. Isr J Med Sci 27:61-66
13. Lipinski B, Lipinska I (2002) Free radical-induced modification of human fibrinogen: implications for atherosclerosis. In: Kostner CM, Kostner KM (eds) Atherosclerosis: risk factors diagnosis and treatment. Monduzzi Editore, USA, pp 149-152
14. Davies K J A, Delsignore MA (1987) Protein damage and degradation by oxygen radicals. III. Modification of secondary and tertiary structure. J Biol Chem 262:9908-9913
15. Inoue H, Hirobe M (1986) Disulfide cleavage and insulin denaturation by active oxygen in copper (II)/ascorbic acid system. Chem Pharm Bull 34:1075-1079
16. Szweda PA, Friguet B, Szweda LI (2002) Proteolysis, free radicals and aging. Free Radic Biol Med 33:29-36
17. Furlan M, Kemp G, Beck EA (1975) Plasmic degradation of human fibrinogen. III. Molecular model of the plasmin-resistant disulfide knot in monomeric fragment D. Biochim Buiophys Acta 400:95-111
18. Lipinski B (2002) Evidence in support of a concept of reductive stress. Br J Nutr 87:93-94
19. Kakhlon O, Cabantchik ZI (2002) The labile iron pool: characterization, measurement, and participation in cellular processes. Free Radic Biol Med 32:1037-1046
20. Kruszewski M (2003) Labile iron pool: the main determinant of cellular response to oxidative stress. Mutat Res. 531:81-92
21. Brewer GJ (2007) Iron and copper toxicity in disease of aging, particularly atherosclerosis and Alzheimer's disease. Exp Biol Med (Maywood) 232:323-335
22. Duffy SJ et al (2001) Iron chelation improves endothelial function in patients with coronary artery disease. Circulation 103:2799-2804
23. Millan M et al (2007) Increased body iron stores are associated with poor outcome after thrombolytic treatment in acute stroke. Stroke 38:90-95
24. Ferrara DE, Taylor WR (2005) Iron chelation and vascular function: in search of the mechanism. Arterioscl Thromb Vasc Biol 25:2235-2237
25. Donovan JM, Daugher R, Bree M, Marguis J (2005) Preclinical and clinical development of deferitrin, a novel, orally available iron chelator. Ann NY Acad Sci 1054:492-494
26. Coudray C, Favier A (2000) Determination of salicylate hydroxylation products as an in vivo oxidative stress marker. Free Radic Biol Med 29:1064-1070
27. Kovac IB, Gorog DA, Yamamoto J (2006) Enhanced spontaneous thrombolysis: a new therapeutic challenge. J Thromb Thrombolysis 21:221-227
28. Karmohapatra SK, Chakraborty K, Kahn NN, Sinha AK (2007) The role of nitric oxide in aspirin induced thrombolysis in vitro and the purification of aspirin activated nitric oxide synthase from human blood platelets. Am J Hematol 82:986-995
29. Ly JV, Zavala JA, Donnan GA (2009) Neuroprotection and thrombolysis: combination therapy in acute ischemic stroke. Expert Opin Pharmacother 10:323-331
30. Anekonda TS (2006) Resveratrol-a boon for treating Alzheimer's disease? Brain Res Rev 52:316-326
31. Campo GM et al (2005) Purified human plasma glycosaminoglycans limit oxidative injury by iron plus ascorbate in skin fibroblast cultures. Toxicology in Vitro 19:561-572
32. Albers GW et al (2004) Antithrombotic and thrombolytic therapy for ischemic stroke. Chest 126:483S-502S